Free-text search
Content Types
-
ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL
The world’s first bitoric hydrophobic monofocal intraocular lens with a non-constant asphericity profile design expands the ZEISS LUCIA Family to treat cataract...
-
David Lang on the future of robotic surgery: More people should gain access
David Lang, Head of the Nordic Region at robotic surgery company Intuitive, delivers the opening address at Medtechdagen 2026 next week. On stage, he will discu...
-
Axoltis moves ALS drug forward after encouraging clinical findings
A new ALS candidate from French company Axoltis Pharma missed its primary endpoint in a Phase II study but showed several positive clinical effects.
-
Sanofi to transfer 20 medicines to Cheplapharm
Sanofi will transfer 20 of its established medicines and three manufacturing sites to Germany‑based Cheplapharm. The move is said to be partly aimed at freeing ...
-
Novo walks away from Ascendis GLP‑1 partnership
Novo is terminating a licensing partnership with Ascendis Pharma, thereby leaving behind a development program in weight management after two years.
-
Lilly is sanctioned for remarks to Swedish media
Eli Lilly is being sanctioned for statements made in an interview with a Swedish newspaper, in which a yet‑to‑be‑approved obesity drug is claimed to “stand in a...
-
Ambu acquires US endoscopy company
Danish medtech company Ambu has acquired US-based TIMS Medical for USD 45m, with additional milestone payments of up to USD 20m.
-
FDA approves first SMA therapy targeting muscle loss
A new type of medication for the rare genetic disease spinal muscular atrophy (SMA) has been approved in the United States.
-
Tataa is acquired by a Dutch firm
The Swedish laboratory company TATAA Biocenter is being acquired by the Dutch CRO Single Cell Discoveries.
-
GSK to close German vaccine plant – 641 jobs at risk
Demand for traditional flu vaccines is declining. GSK is now consolidating production in Canada and closing its plant in Dresden, putting 641 jobs at risk.
-
Tandem Health raises $100m to expand in Europe
Swedish AI company Tandem Health has raised $100m. The funding will be used to strengthen the company’s position in Europe.
-
Etcamah misses main goal after recent FDA approval
AstraZeneca’s tablet therapy Etcamah for breast cancer has failed to meet the primary endpoint in a Phase III study, the company reports. The announcement comes...
-
Danish pharma giant shortens name – becomes Novo
A shorter name, a new corporate culture and a faster pace. Novo Nordisk is overhauling its brand as the pharmaceutical giant seeks to move faster and sharpen it...
-
Introducing ZEISS VersaXRM 5 Insight
Stay in the flow from overview to insight.
-
More details emerge about QuantumCell’s operational team
Jesper Bastlund has joined biotech start-up QuantumCell as Vice President of Biology and Translational Science, according to a post on LinkedIn.
-
Two nordic paths to fewer RSV admissions
Antibodies and vaccines are having major impact on infant hospitalizations.
-
Alzinova strengthens its cash position ahead of Phase II study
The Swedish research company Alzinova has initiated the start‑up phase of its Phase II study in Alzheimer’s disease – and is simultaneously announcing a rights ...
-
US boost for Lundbeck’s Cushing’s drug candidate
Lundbeck has received orphan drug designation from the US FDA for asedebart, Lu AG13909, for the treatment of endogenous Cushing’s syndrome.
-
Sectra scales up in Denmark’s new eastern region
When Region Hovedstaden and Region Sjælland merge to form Region Østdanmark, Sectra’s medical imaging service Sectra One will be expanded to all hospitals in the region.
-
Getinge aims to expand in transplantation – with an eye on China
The Swedish medtech company Getinge plans to expand within organ transplantation in Europe and Asia, says CEO Mattias Perjos.
-
Meet ZEISS Microscopy at ECP 2026 in Stockholm
Visit our booth 12-16 September, 2026.
-
CordenPharma targets 500m injectable units with €80m expansion
CordenPharma is investing €80m to significantly expand its manufacturing capacity for sterile injectable medicines in Italy. Once completed, the site will be ab...
-
Marie Gårdmark: Are FDA and EMA drifting apart?
Are FDA and EMA beginning to drift apart on what it takes to approve new medicines? And what could that mean for drug development on both sides of the Atlantic?...
-
How SweTrial aims to bring more clinical trials to Sweden
Sweden has lost ground in clinical trials. SweTrial now aims to reverse the trend, but both the Swedish Medical Products Agency and the pharmaceutical industry ...
BREAKING